News About: Pharm. Industry
Hanmi Chairman Lim named Asia's Best CEO
Hanmi Pharm Chairman Lim Sung-ki was nominated Asia's Best CEO from Institutional Investor magazine.
In a ceremony held in Hanmi Headquarters in Seoul, Lim was given the CEO honor in the healthcare and pharmaceutic...
Bukwang, BMS Korea set to challenge GSK's hepatitis B medicines in second quarter
Domestic hepatitis B market is heating up as Bukwang Pharm's Levovir (clevudine) and BMS Korea's Baraclude (entecavir) are poised to snatch up a large share of GlaxoSmithKline's Zeffix (lamivudine) and Hepsera (adefov...
Drug incentive bill likely to be scrapped
The controversial drug incentive bill, which benefits doctors who prescribe low-priced drugs, could be abolished, according to sources on February 21.
The National Assembly decided to defer the bill until February ...
Amlodipine generic makers gear up for sales boost
Dong-A Pharmaceutical Co., one of Korea's leading amlodipine generic makers, is putting more and more efforts into hospital marketing in a step to raise sales on domestic antihypertensive market.
The company's Oro...
Hanmi Chairman Lim Sung-ki, the wealthiest in pharmaceutical industryChairman Lim Sung-ki of Hanmi Pharm is the richest owner in the domestic pharmaceutical industry as his assets are worth 268.8 billion won by share's value, according to local a...
|
New drug policy perplexes GSK
As the government decided to exclude Tykerb (lapatinib) from the list of national health insurance last month, GlaxoSmithKline is in dilemma to launch the product, saying it would limit Korean patients' access to newl...
Prosecution unveils fabricated test results of 6 generic drugs
The prosecution announced on February 20 that local bioresearch centers falsified test results for six generic drugs each produced by six local companies.
The drugs include Hyundai Pharm's Levotuss, Hanmi Pharm's F...
Debates rekindled on government's stern measures on generic data fabrication
The controversy over the bioequivalence data fabrication has flared again following the government's unilateral administrative measure to cancel the licenses of generic drugs without lawful procedures.
In response ...
CJ to invest $2.5 million in Neuralstem Inc.
CJ CheilJedang Corporation, a subsidiary company of CJ Group, said on February 20 that it has purchased an option to negotiate for the exclusive license to Neuralstem's stem cell-products and technology after the comp...
Some prescription drugs in shot supply
Major pharmaceutical manufacturers, including Yuhan Corporation, have been shying away from providing some of ethical products over the years without expansion of their production capacity, making it difficult for who...
